You are here: Industry Insights > PeptiDream

News List

Alnylam and PeptiDream Enter into Collaboration Agreement to Discover and Develop Peptide-siRNA Conjugates for Targeted Delivery of RNAi Therapeutics to a Broader Range of Extrahepatic Tissues firstwordpharma
July 30, 2021
Alnylam Pharmaceuticals, Inc.(Nasdaq: ALNY) announced today a license and collaboration agreement to discover and develop peptide-siRNA conjugates to create multiple opportunities to deliver RNAi therapeutics to tissues outside the liver.
PeptiDream and Merck partner to develop Covid-19 therapeutics pharmaceutical-technology
June 15, 2020
Japanese biopharmaceutical firm PeptiDream has partnered with Merck (MSD) to discover and develop new peptide therapeutics which could neutralise SARS-CoV-2, the novel coronavirus that causes Covid-19.
PeptiDream and Shionogi sign peptide drug conjugate discovery deal pharmaceutical-technology
January 24, 2019
PeptiDream has signed a deal with fellow Japanese pharmaceutical company Shionogi to discover and develop a series of blood-brain barrier (BBB) penetrating peptide drug conjugates.